Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence

Background: Blockade of the cytokine interleukin-1 (IL-1) with IL-1 receptor antagonist (IL-1Ra) is a candidate treatment for stroke entering phase II/III trials, which acts by inhibiting harmful inflammatory responses.  Infection is a common complication after stroke that significantly worsens outc...

Descripción completa

Detalles Bibliográficos
Autores principales: McCulloch, Laura, Allan, Stuart M., Emsley, Hedley C., Smith, Craig J., McColl, Barry W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820822/
https://www.ncbi.nlm.nih.gov/pubmed/31700615
http://dx.doi.org/10.12688/f1000research.19308.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820822/
https://www.ncbi.nlm.nih.gov/pubmed/31700615
http://dx.doi.org/10.12688/f1000research.19308.2

Ejemplares similares